BackLakeShore Biopharma Co Ltd. - Warrants (15/03/2028) Overview
LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)

LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) Debt to Equity

Valuation check: LSBPW's debt-to-equity ratio is 0.84, above the sector sector average of 0.2.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

0.84

Debt to Equity

0.84

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) (LSBPW) FAQ

The latest debt-to-equity ratio for LSBPW is 0.84. That is above the sector sector average of 0.2. Investors often review this figure alongside LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, LSBPW currently prints 0.84 for debt-to-equity ratio, while the sector average sits near 0.2. That is roughly 317.3% above the sector mean. Large gaps often invite a closer look at LakeShore Biopharma Co Ltd. - Warrants (15/03/2028)'s growth, margins, and balance sheet.

A debt-to-equity ratio of 0.84 for LakeShore Biopharma Co Ltd. - Warrants (15/03/2028) is not 'good' or 'bad' on its own. Compare it with the peer average (0.2) and with LSBPW's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting LSBPW's debt-to-equity ratio (0.84), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.